Cardiac Symptoms in Patients With Treated Graves' Disease
NCT ID: NCT06908369
Last Updated: 2025-04-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
75 participants
OBSERVATIONAL
2021-09-20
2025-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators conducted a questionnaire survey which showed that about 38% of patients with Graves' disease continue to experience cardiac symptoms even months after normalization of thyroid hormone concentrations in the blood. This observation supports the presence of a persistent cardiovascular dysfunction, which may be due to a modulation of genomic or non-genomic factors with an effect on the cardiovascular system. These reflections are the focus of this clinical study. The aim of the study is to investigate the possible pathophysiology for this new "syndrome" in biochemically euthyroid patients. It is not a repetition of previous similar experiments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism
NCT04932135
Primary Hyperparathyroidism: Non-classical Manifestations
NCT00432939
Heart Rate Monitoring by Wearable Devices in Graves' Disease
NCT04333342
Thyrotropin Over-suppression and Heart
NCT02645786
Subtotal Versus Total Thyroidectomy for Graves' Disease
NCT01408368
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 75 patients are included in the study. Patients were recruited from the Department of Nephrology and Endocrinology at Copenhagen University Hospital Rigshospitalet and the Department of Internal Medicine, Section of Endocrinology at Herlev Gentofte Hospital, Denmark. The patients were identified by extracting a list of patients with the International Classification of Diseases 10 codes (ICD 10 codes) E050 and E059. Also, a list of patients with positive thyrotropin receptor antibody (TRAbI measurements was extracted.
All patients had a thorough cardiac work up including blood samples, 12-lead resting electrocardiogram, 24-hour electrocardiogram monitoring (Holter), transthoracic echocardiography, and exercise stress test. The focus was to investigate whether the cardiac symptoms could be explained by structural or functional changes of the heart or by cardiac arrhythmias.
All patients were questioned about their symptoms including: type of cardiac symptoms, frequency and when they occured. The focus was to gain knowledge on the clinical presentation of cardiac symptoms in the subgroup.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with treated Graves' disease and cardiac symptoms
Patients with Graves' disease, who have been treated to biochemical euthyroidism but still experience cardiac symptoms.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between the ages of 18 and 55 years
* Has been euthyroid for at least three months prior to inclusion
* Experiences cardiac symptoms
Exclusion Criteria
* Deemed unsuitable by project staff (e.g. due to language problems)
* Pregnancy
* Alcohol abuse or other abuses
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ulla Feldt-Rasmussen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ulla Feldt-Rasmussen
MD, DMSc, Professor Emerita, Senior Research Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulla Feldt-Rasmussen, MD; DMSc
Role: STUDY_DIRECTOR
Rigshospitalet, Denmark
Stig Haunsø, MD; DMSc
Role: STUDY_DIRECTOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Rigshospitalet, Capital Region
Identifier Type: OTHER
Identifier Source: secondary_id
Cardiac Symptoms in Graves
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.